Lamotrigine

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released December 16, 1998; last updated September 18, 2017; expires September 18, 2020

This article includes discussion of lamotrigine, Lamictal, and Plexxo. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Historical note and terminology

The era of antiepileptic drugs started with the introduction of bromides in 1857. It was followed by the discovery of the anticonvulsant effect of barbiturates in 1912 and the introduction of hydantoins in 1916. Carbamazepine was introduced into clinical practice as an antiepileptic drug in 1963. Carbamazepine as well as lamotrigine blocks the repetitive firing of neurons by blocking sodium channels. Unrelated to any previous antiepileptic drug, lamotrigine reduces presynaptic excitatory amino acid release. Like most other antiepileptic drugs, the discovery of lamotrigine was serendipitous. Its discovery was based on the suggestion that the antiepileptic effect of phenytoin and phenobarbital is due to the disturbances of folate metabolism caused by these drugs (Reynolds et al 1966). This led to an investigation of a number of folate antagonists in animal models, including phenyltriazines with strong antiepileptic action, even though the antifolate action was mild. Lamotrigine was developed from this category of compounds for treatment of partial seizures in 1995. It is approved worldwide.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.